Carfilzomib
Common brands: Kyprolis, Maxidex, Dexamethasone 1.5 Mg, Hemady, Ozurdex
Top reporter: Onyx Pharmaceuticals, Inc.
Proteasome Inhibitor [EPC]Corticosteroid [EPC]Thalidomide Analog [EPC]CD38-directed Cytolytic Antibody [EPC]Alkylating Drug [EPC]
27,745
Total Reports
13,151
Serious Reports
4,329
Death Reports
30
Reported Reactions
Death Report Ratio: High (15.60%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Carfilzomib.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | PLASMA CELL MYELOMA | 2,989 | |
| 2 | OFF LABEL USE | 2,359 | |
| 3 | DEATH | 1,757 | |
| 4 | FATIGUE | 1,529 | |
| 5 | THROMBOCYTOPENIA | 1,516 | |
| 6 | PNEUMONIA | 1,364 | |
| 7 | PYREXIA | 1,157 | |
| 8 | DIARRHOEA | 1,114 | |
| 9 | DYSPNOEA | 1,113 | |
| 10 | ANAEMIA | 1,104 | |
| 11 | NEUTROPENIA | 1,092 | |
| 12 | NAUSEA | 1,063 | |
| 13 | ACUTE KIDNEY INJURY | 854 | |
| 14 | DRUG INEFFECTIVE | 836 | |
| 15 | ASTHENIA | 705 | |
| 16 | HYPERTENSION | 704 | |
| 17 | DISEASE PROGRESSION | 687 | |
| 18 | NEUROPATHY PERIPHERAL | 681 | |
| 19 | INFECTION | 653 | |
| 20 | PLATELET COUNT DECREASED | 595 | |
| 21 | SEPSIS | 583 | |
| 22 | CARDIAC FAILURE | 548 | |
| 23 | THERAPY PARTIAL RESPONDER | 543 | |
| 24 | VOMITING | 524 | |
| 25 | COVID-19 | 487 | |
| 26 | RENAL FAILURE | 465 | |
| 27 | PANCYTOPENIA | 443 | |
| 28 | RASH | 438 | |
| 29 | MALAISE | 433 | |
| 30 | PLASMA CELL MYELOMA REFRACTORY | 427 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.